Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNK001 in Advanced Or Metastatic Clear Cell Renal Cell Carcinoma
NCT07564232Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2026
- Primary completion
- Jun 2031
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LNK001 in clear cell renal cell carcinoma (ccRCC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and Adverse Events at 1 year. Started Jul 2026; status: recruiting.
02
Drugs
LNK001
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07564232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07564232.